Pancreatic cancer is one of the most common malignant tumors. Due to late diagnosis and a lack of effective treatments, pancreatic cancer has a poor prognosis and a high mortality rate. Further understanding of the mechanisms underlying the development and progression of pancreatic cancer is key to developing rational diagnostic and therapeutic strategies. Exosomes are small vesicles secreted by most cells, carrying a rich cargo of lipids, proteins and nucleic acids. Exosomes serve various roles in intercellular communication, biological processes and signal transduction. Notably, exosomes exhibit a dual role in pancreatic cancer: Exosomes can directly promote tumor cell proliferation, growth and metastasis, modulate the complex immunosuppressive microenvironment and contribute to chemoresistance; by contrast, exosomes can serve as biomarkers for diagnosis and drug delivery vehicles. The present study systematically reviewed the mechanisms through which exosomes exert their dual functions via their specific biomolecular cargo in pancreatic cancer, as well as their potential applications in diagnosis and treatment, thereby laying a research foundation for exosomes to potentially serve a more active role in pancreatic cancer in the future.
exosomespancreatic cancertumor microenvironmentintercellular communicationdrug deliveryFunding: No funding was received.Introduction
Pancreatic cancer (PC) is a fatal disease, with ~51,980 deaths in the US each year and a 5-year survival rate of only 13%, making it a malignancy with one of the worst prognosis among all cancer types (1). Currently, the primary clinical treatments for PC include surgical resection and chemotherapy. However, due to the aggressive progression of the disease and the fact that ~80% of patients are diagnosed at an advanced stage, surgical resection is often not feasible (2). Even the modified version of folinic acid, irinotecan and oxaliplatin (mFOLFIRINOX) chemotherapy regimen, which is considered one of the most effective treatments for PC, achieves a 3-year overall survival rate of merely 63.4% (3). mFOLFIRINOX is an effective combined chemotherapy regimen. The name is derived from the abbreviations of its four constituent drugs: FOL, FIRI and NOX. The prefix ‘m’ indicates ‘improved’. This regimen was developed by the classic FOLFIRINOX protocol. Currently, it is mainly used as a first-line treatment option for patients with good physical condition who have locally advanced or metastatic PC. FOLFIRINOX is currently one of the key chemotherapy regimens in the field of PC. However, chemotherapy for PC is often limited by two major challenges: The development of chemoresistance, which prevents patients from completing the full course of treatment and the cumulative toxicity of prolonged regimens. Therefore, both treatment efficacy and quality of life of patients are compromised (4). The exact etiology of PC remains to be elucidated; however, the tumor microenvironment (TME), environmental factors and genetic predisposition are recognized as major contributors to its initiation and progression (5). For instance, smoking is the primary non-genetic factor associated with an increased risk of pancreatic ductal adenocarcinoma (PDAC), with an odds ratio of 3.7 (95% confidence interval: 1.8–7.6) (6). Additionally, smoking is significantly associated with a notable decrease in the average age of diagnosis among patients with familial PDAC. These findings underscore the critical role of smoking-related environmental factors in the pathogenesis and progression of PDAC (7,8). The TME of PC consists of cancer, stromal and immune cells and extracellular matrix components, all of which serve key roles in promoting tumor growth and metastasis (9). Key features include driver gene mutations in cancer cells, excessive collagen and extracellular matrix deposition by stromal cells leading to tissue fibrosis and markedly expressed inflammatory cytokines that create a pro-inflammatory and immunosuppressive milieu. This unique TME not only presents a notable barrier to treatment but also offers potential targets for novel therapeutic strategies. Therefore, developing early diagnostic methods and effective treatments for PC remains an urgent and key challenge.
Exosomes are a type of extracellular vesicle (EV) with a diameter of 30–150 nm. Exosomes carry a diverse cargo of lipids, proteins and nucleic acids (10), enabling them to serve as exceptional messengers for complex information transfer between cells (11), across distant tissues (12) and between tumor and stromal compartments (13). Exosomes are present in nearly all bodily fluids, including blood, sweat, tears, urine, saliva, breast milk, ascites and cerebrospinal fluid. Exosomes derived from different sources can exert distinct effects on tumors (14). Tumor-derived exosomes can transfer oncogenic molecules (15), promote anti-apoptotic effects (16), stimulate angiogenesis (17) and alter tumor cell metabolism (18), thereby facilitating tumor growth. However, a previous study has also demonstrated that exosomes hold promise as biomarkers for the early diagnosis of PC (19). Furthermore, exosomes can serve as notable drug delivery vehicles, offering potential therapeutic strategies for an extensive subset of patients with PC with chemoresistance (20). Furthermore, elucidating the interrelationship between the TME of PC and exosomes may help researchers identify novel therapeutic targets, thereby opening novel avenues for treatment. Thus, exosomes serve a dual role in PC. The present review aims to summarize the mechanisms underlying the dual functions of exosomes in the initiation and progression of PC, provide novel insights and directions in optimally utilizing exosomes in clinical therapy and accelerate the clinical translation of exosome-based targeted therapies for PC.
ExosomesOrigin and isolation of exosomes
In 1946, Chargaff and West (21) identified a coagulation factor resembling thromboplastic protein in the blood of patients with hemophilia and bleeding disorders, which is considered the starting point of the field of EV biology. Currently, EVs are categorized into three types based on their diameter and release mechanisms: Exosomes (30–150 nm), microvesicles (100–1,000 nm) and apoptotic bodies (500–5,000 nm), exosomes, which are released upon fusion of multivesicular bodies with the plasma membrane; microvesicles, which bud directly from the plasma membrane; and apoptotic bodies, which are generated during apoptosis via cell membrane blebbing. These three types of vesicles differ in size, formation mechanisms and biological functions, collectively serving as important mediators of intercellular communication (Fig. 1). Exosomes, a type of EV, were identified in 1981 by Trams et al (22) in the supernatant of cultured sheep reticulocytes. In 1987, Johnstone et al (23) named them ‘exosomes’. The cellular origin and purity of exosomes serve a key role in processes such as the occurrence, metastasis and drug resistance of PC. Therefore, the development of efficient and specific techniques for the isolation and extraction of exosomes is of notable importance for research on the mechanisms of PC and its clinical applications. Several exosome isolation techniques have been developed to date, including ultracentrifugation (24), ultrafiltration (25), size-exclusion chromatography (26), precipitation-based isolation (27), immunoaffinity capture (28) and microchip-based technology (29). Each of these techniques has its own principles, advantages and disadvantages (30). However, each technique has certain limitations and fails to meet the expectations of being efficient, high in purity, simple and low in cost. Therefore, the effective, accurate and efficient isolation of high-purity exosomes remains a major challenge (31).
Biogenesis and composition of exosomes
The biogenesis and synthesis of exosomes is a complex process, which begins with endocytosis at the cell membrane surface, where early endosomes are formed through inward budding. Over time, early endosomes mature into late endosomes. Late endosomes primarily form intraluminal vesicles (ILVs) through three pathways: Endosomal sorting complex required for transport, tetraspanin proteins and ceramide induction, and these ILVs gradually develop into multivesicular bodies (MVBs) (32–34). Subsequently, most MVBs fuse with lysosomes, leading to the degradation of ILVs, while a small number of MVBs fuse with the plasma membrane and release exosomes into the extracellular environment (32,35,36). Exosomes carry a rich cargo of lipids, proteins and nucleic acids. The lipid components in exosomes include cholesterol, sphingomyelin, glycosphingolipids, phosphatidylserine, phosphatidylinositol, phosphatidic acid and ceramide (37). Common proteins in exosomes include those associated with membrane transport, such as Ras-related in brain GTPases, annexins, flotillins and MVB biogenesis proteins including apoptosis-linked gene 2-interacting protein X (38). Exosomes also contain tetraspanin proteins, including CD9, CD63 and CD81, as well as heat shock proteins (HSP) such as HSP60 and HSP90. The nucleic acid components in exosomes are also highly diverse, such as microRNA (miRNA/miR) and messenger RNA, which were among the first two types identified (39,40), followed by long non-coding RNA (lncRNA), transfer RNA, small nuclear RNA and circular RNA (circRNA/circ) (39,41) (Fig. 2). These RNA not only act as regulators of gene expression but also serve as potential biomarkers (42). For instance, miR-141 can be detected in the blood of patients with prostate cancer, and its expression level is correlated with the size and malignancy of the tumor (43). Saliva miR-3679-5p and miR-940 have good discriminatory ability and can be used for the detection of resectable PC, with reasonable specificity and sensitivity (44). Furthermore, lncRNA can be regarded as an independent predictor of pathological cardiac remodeling and diastolic dysfunction in patients with type 2 diabetes (45).
‘Dark side’ of exosomes: Promoting the initiation and progression of PC
Exosomes serve a non-negligible ‘dark’ role in the initiation and progression of PC, driving tumor development and inducing therapy resistance through multiple mechanisms. Specifically, exosomes serve as key mediators of intercellular communication and can be derived from various cell types, including PC cells, adipocytes, cancer-associated fibroblasts (CAFs) and immune cells (46,47). By carrying specific molecules such as miRNAs, proteins and circRNAs, exosomes activate multiple signaling pathways [such as signal transducer and activator of transcription 3 (STAT3), hypoxia inducible factor 1α (HIF-1α), epidermal growth factor receptor/mitogen-activated protein kinase (EGFR/MAPK)], directly promoting tumor cell proliferation, invasion and metastasis. Simultaneously, exosomes act as key modulators of the immunosuppressive TME. Exosomes can induce M2 macrophage polarization and regulate pathways such as protein kinase B/extracellular signal-regulated kinase (AKT/ERK), establishing a local environment conducive to immune evasion and tumor metastasis. Furthermore, exosomes notably contribute to chemoresistance. They can function as drug efflux pumps or deliver miRNAs (such as miR-155 and miR-210) to inhibit apoptosis and ferroptosis, thereby mediating resistance to gemcitabine. Furthermore, exosomes can also promote the progression of PC by regulating lipid metabolism and the TME (Table I) (48–66). These findings not only highlight exosomes as key drivers of malignant progression in PC but also provide a theoretical basis in targeting them to reverse drug resistance and improve therapeutic efficacy (Fig. 3).
Drives tumor growth and cell proliferation
Exosomes can drive the proliferation of tumor cells through multiple signaling pathways. The mechanism of their action mainly involves exosomes derived from tumor cells, CAFs and immune cells. A previous study using in vitro cell models reported that exosomes derived from cancer-associated adipocytes generated by co-culturing human adipocytes with human PC cells could promote the proliferation, invasion, migration and drug resistance of PC cells through the suppressor of cytokine signaling 7/STAT3/serum amyloid A1 pathway (48). Similarly, Zhang et al (49) reported that exosomes derived from CAFs could promote the proliferation of PC cells by regulating Abelson murine leukemia viral oncogene homolog 2 through miR-224-3p. Based on an in vivo animal model study, Zhou et al (50) reported that exosomes derived from CAFs could also exert effects through the silent information regulator 3/histone 3 lysine 9 acetylation/HIF-1α axis.
By contrast, exosomes secreted by PC cells themselves also serve a key role in tumor progression. For example, miR-519a/522-5p in exosomes can promote PC progression by enhancing the Warburg effect (51), miR-3960 promotes the proliferation, invasion and metastasis of PC cells through the transcription factor activator protein-2α axis (52), and the DnaJ heat shock protein family (HSP40) member B11 protein participates in PC progression by regulating the EGFR/MAPK pathway (53). Furthermore, exosomes derived from immune cells also regulate the progression of PC. For instance, miR-202-5p and miR-142-5p in exosomes derived from macrophages can enhance the invasiveness of PC cells and promote the metastasis of pancreatic ductal adenocarcinoma (54). In addition, exosomes derived from M2-type macrophages can further support tumor growth by targeting E2F transcription factor 2 and inducing tumor angiogenesis (55). These results collectively indicated that exosomes can jointly serve a role in promoting the occurrence and development of PC through various mechanisms.
Shapes the immunosuppressive microenvironment
The mechanism by which exosomes promote the progression of PC by shaping an immunosuppressive microenvironment has been a notable research direction in this field. Although existing studies have revealed the relevant pathways, the strength of the evidence varies, mainly based on in vitro cell models or in vivo animal models. In in vitro cell models, it has been reported that exosomes derived from PC cells can induce M2-type macrophage polarization by delivering miR-510 and lncRNA FGD5-AS1, thereby enhancing the vitality, migration and invasion of cancer cells (56,57). In in vivo animal models, the relevant mechanisms of action have been further verified and expanded. For example, Yang et al (58) reported that exosomes derived from CAFs can carry prostaglandin-endoperoxide synthase 2 and induce M2-type macrophage polarization by activating the nucleotide-binding oligomerization domain-containing protein 1, thereby promoting the metastasis of PC. The exosomes of tumor-associated macrophages, through the tyrosine kinase-binding protein, promote the metastasis process of PC via the CD44/AKT/ERK pathway (59). These results revealed the multi-cellular origin and multi-pathway synergy of exosomes in shaping the immunosuppressive microenvironment, providing key clues for further understanding of the progression mechanism of PC.
Induces therapy resistance
PC is prone to develop treatment resistance at an early stage, markedly threatening the life and quality of life of patients. Currently, the mechanism of drug resistance in PC has not been fully elucidated, but exosomes may serve a key role in this process. Exosomes may mediate PC resistance through multiple pathways (67). They can either remove drugs from cancer cells directly or deliver miRNA mutations or upregulated proteins to drug-sensitive cells to exert an indirect effect (20,68,69). The drug resistance mechanism of exosomes has been further clarified in different research models. In vitro cell models have demonstrated that exosomes derived from PC cells can upregulate STAT3 expression by inhibiting miR-298 through protein phosphatase 3 catalytic subunit β (60). Furthermore, exosomes can induce the high expression level of ATP-binding cassette sub-family G member 2 as a drug efflux pump in cells in vitro (61). The miR-210 in exosomes derived from PC stem cells can trigger the mTOR signaling pathway, thereby inducing gemcitabine resistance (62).
In vivo animal models have further identified that exosomes derived from CAFs can inhibit ferroptosis by mediating the acyl-CoA synthetase long-chain family member 4 pathway through miR-3173-5p, thereby enhancing the resistance of PC cells to gemcitabine (63). Of note, the clinical sample analysis supported the hypothesis that exosomes derived from PC cells, carrying miR-155, target tumor protein 53 inducible nuclear protein 1 and inhibit apoptosis, thereby contributing to the drug resistance mechanism (64). These findings revealed the multi-level and multi-pathway regulatory role of exosomes in PC resistance, providing notable evidence in further understanding of the resistance mechanism and the development of reversal strategies.
Regulates lipid metabolism and the TME
Exosomes participate in metabolic reprogramming and immune microenvironment remodeling in PC by delivering lipid metabolism-related molecules. For instance, previous research indicated that the fatty acid binding protein 7 in macrophages can transfer the induced lipids to CD8+ T cells and tumor cells through exosomes. This process leads to dysfunction of CD8+ T cells and proliferation of tumor cells through metabolic reprogramming (65). Furthermore, a previous study demonstrated that the medium-chain acyl-CoA dehydrogenase present in exosomes enhances gemcitabine resistance by regulating fatty acid metabolism and ferroptosis in PC (66). These findings indicated that exosomes serve not only as carriers but also as key mediators of lipid metabolic reprogramming, indirectly regulating the immunosuppressive state of the TME through metabolic intervention.
Although exosomes serve an undeniable ‘dark side’ role in the occurrence and development of PC, they can promote disease progression by directly driving tumor growth and cell proliferation, shaping an immunosuppressive microenvironment and inducing treatment resistance. However, its unique biological characteristics also provide a novel ‘bright side’ role for the treatment of PC. This duality of opposites lays the foundation for its transformation from a disease promoter to a diagnostic and therapeutic tool. Based on further understanding of the mechanism of action of exosomes in PC, researchers are actively developing their application potential in early diagnosis, targeted therapy and drug resistance reversal, thereby maximizing the positive role of exosomes in PC. The following section systematically elaborates on the latest research progress of exosomes as diagnostic markers, direct therapeutic tools and drug delivery carriers.
‘Bright side’ of exosomes: Potential for diagnosis and treatment of PC
In recent years, exosomes have demonstrated notable ‘bright side’ potential in the diagnosis and treatment of PC. In terms of diagnosis, due to the protective effects of their lipid bilayer membrane and the CD47 transmembrane protein, exosomes carrying PC-specific information remain relatively stable in the circulatory system and are less susceptible to clearance by monocytes. This stability provides a possibility for early diagnosis through liquid biopsy (70–72). Regarding therapeutic applications, exosomes exhibit a key role: i) Exosomes can function as natural therapeutic agents originating directly from immune cells or stem cells, capable of effectively inhibiting tumor cell proliferation and selectively killing cancer cells; ii) exosomes represent a highly promising class of drug delivery vehicles. By loading chemotherapeutic drugs or immunomodulators, exosomes enable precise targeting to overcome drug resistance and reprogram the TME, thereby offering notable potential for effective PC treatment; and iii) exosomes can exert an active effect through the ‘exosome-lipid metabolism-TME’ axis (Table II) (73–86) (Fig. 4).
Exosomes as a biomarker for liquid biopsy
In recent years, exosomes have demonstrated potential to serve as a biomarker for the early diagnosis of PC. Several studies based on clinical samples have systematically verified their value. In 2022, Odaka et al (73) identified that CD63+ cells in serum-derived exosomes and CD41/CD61+ cells in platelet-derived exosomes serve as potential diagnostic biomarkers for pancreatic ductal adenocarcinoma. Furthermore, miR-451a in serum-derived exosomes (74), as well as G protein-coupled receptor class C group 5 member C and EGFR pathway substrate 8 (75) have been proposed as candidate markers for the early detection of PC. In the same year, further research revealed that high expression levels of circRNAs (hsa_circ_0001666 and hsa_circ_0006220) in plasma-derived exosomes also possess diagnostic value (76). miR-20a, which is present in exosomes derived from duodenal fluid, has also been proposed as a biomarker for pancreatic ductal adenocarcinoma (77). These findings were all based on systematic validation using clinical samples and had a high level of evidence strength.
Furthermore, in order to enhance the sensitivity and specificity of exosome detection, novel detection technologies are constantly emerging. For example, Li et al (87) constructed an immunoassay system based on a hierarchical surface-enhanced Raman scattering substrate, enabling highly sensitive detection of exosomes. The study identified that a novel combination of leucine-rich α-2-glycoprotein 1-derived exosomes and glypican-1-derived exosomes could enhance the diagnostic efficiency for PC. Yu et al (88) developed a simple nanoliquid biopsy method that achieves specific, ultrasensitive and cost-effective exosome detection through a dual-specific biomarker antigen co-recognition and capture strategy. Yin et al (89) designed a graphene field-effect transistor-based biosensor for accurate and rapid detection of PC-associated exosomes. These technological advancements have collectively facilitated the transformation of exosomes from biomarker identification to clinical application, providing a multi-level solution for the early diagnosis of PC.
Exosomes as a direct tool for the treatment of PC
Exosomes can serve as a direct therapeutic tool in inhibiting the development of PC and their effects have been verified through various research models. In in vitro cell models, exosomes derived from multiple cell sources exhibited clear antitumor activity. For instance, exosomes derived from natural killer cells can upregulate the expression level of let-7b-5p in PC cells and target the cell cycle regulatory factor CDK6, thereby inhibiting tumor cell proliferation (78). Furthermore, Hasoglu and Karatug Kacar (79) identified that exosomes derived from pancreatic islet progenitor cells can selectively kill PC cells without notable damage to normal cells, demonstrating good biological safety. In in vivo animal models, these therapeutic potentialities can be further verified. A previous study has demonstrated that exosomes derived from umbilical cord blood natural killer cells can enter PANC-1 cells through endocytosis, induce mitochondrial oxidative damage and inhibit the progression of this cell line, revealing a marked anti-PC effect (80). Furthermore, miR-124 contained in exosomes derived from bone marrow mesenchymal stem cells (BMSCs) has also exhibited anti-PC activity in both in vitro and in vivo experiments (81). These studies collectively demonstrated that exosomes have the potential for multi-mechanism synergy, extensive sources and good safety in the treatment of PC, providing notable basis for the development of novel biological therapies.
Exosomes as a carrier for drug delivery
Exosomes, as an efficient drug delivery carrier, are expected to provide a safer and more effective delivery strategy for traditional anti-PC drugs due to their notable biocompatibility and low toxicity (90,91). An in vitro cell model study demonstrated that exosomes derived from human BMSCs carrying gemcitabine can enhance apoptosis to inhibit the proliferation of PC cells, thereby inhibiting the progression of PC (82). Furthermore, exosomes derived from M1-type macrophages loaded with gemcitabine and deferasirox can effectively overcome drug resistance and provide a potential effective treatment strategy for patients with PC with drug resistance (83). The in vivo animal models further demonstrated the therapeutic advantages of the exosome delivery system, autologous exosomes carrying gemcitabine can markedly promote the uptake of the drug in cancer cells and enhance its antitumor effect (84). Furthermore, the emerging engineered exosome platform offers a novel direction for the regulation of the TME; for instance, Sun et al (92) developed a novel exosome-based drug delivery platform, cmExoaCD11b, aiming to precisely target and reprogram the TME for immunotherapy of PC. This technology can cause M2 macrophages to polarize to the M1 phenotype, thereby reprogramming the TME and markedly inhibiting the development of PC. These studies collectively demonstrated that exosomes not only serve as efficient drug carriers but can also achieve multi-mechanism synergistic antitumor effects through dynamic interactions with the TME.
Of note, exosomes derived from M1-type macrophages can inhibit the lipid metabolism pathway, thereby reducing the proliferation, migratory and invasive abilities of PC cells, while simultaneously promoting their apoptosis (85). Furthermore, a previous study has demonstrated that exosomes may be involved in lipid metabolism and regulate the TME, thereby participating in multiple processes of PC (86). These findings provided novel insights in developing metabolism-targeted exosome-based therapies.
Challenges and future directions
In summary, the present review systematically elaborated on the dual roles of exosomes in PC and their specific mechanisms of action. Exosomes serve a positive role in the treatment of PC, however, their involvement in regulating PC cells, shaping an immunosuppressive microenvironment and promoting chemotherapy resistance remains to be explored in future research. Further exploration of the key molecules, proteins and signaling pathways underlying these adverse effects may provide novel research directions and intervention strategies for targeted therapy of PC.
However, numerous challenges remain in realizing the optimal application of exosomes for PC therapy. First, current techniques in isolating and extracting exosomes face notable limitations (93). Although multiple methods are available, such as ultracentrifugation and size-exclusion chromatography, a standardized protocol that simultaneously ensures high purity, simplicity and low cost is still lacking (94,95). Establishing a unified separation standard for exosomes is of notable importance for the reproducibility of research and cross-study comparisons. Second, the diameter of exosomes ranges from 30–150 nm, which is below the diffraction limit of conventional optical microscopy. This poses notable challenges in visualizing the release, transport and real-time dynamics of exosomes. In recent years, super-resolution microscopy holds promise in resolving exosomal ultrastructure; its high spatial resolution often comes at the expense of temporal efficiency, making dynamic studies in living cells particularly challenging (96,97). Third, the extraction of exosomes remains costly. While obtaining exosomes from patient urine or saliva is a non-invasive approach with certain practical advantages, the process is often time-consuming and requires notable financial investment (98). Of note, in recent years, EVs extracted from natural plants or food sources have successively demonstrated notable biocompatibility and therapeutic potential, providing a key direction and research breakthrough in reducing extraction costs and developing stable and controllable EV resources (99,100). Fourth, although exosomes exhibit notable promise as drug delivery vehicles, key issues such as high loss rates during drug loading and elevated production costs should be addressed (101). Currently, the use of serum-free culture systems to optimize the production process of exosomes, as well as the development of synthetic biomimetic vesicles with similar functions, provide a feasible technical direction in addressing these issues (102). Fifth, there is a notable lack of clinical data. Current research on exosome-based therapies for PC is largely limited to in vitro studies and in vivo mouse models. However, human clinical trials are still lacking (78,82,84). To promote its clinical application, the following key steps need to be clarified: i) Pharmacological and toxicological research are warranted to elucidate the pharmacokinetic and pharmacodynamic characteristics, biodistribution and potential immunogenicity of exosomes in the body; ii) in-depth clinical trials; and iii) progressive research from safety assessment to efficacy validation. Sixth, future studies should further elucidate how exosomes regulate the TME through lipid metabolism reprogramming, particularly their role in metabolic-immune crosstalk. The development of therapeutic strategies targeting exosomal lipid metabolism, such as exosome-based delivery systems for metabolic enzyme inhibitors, may potentially offer novel avenues in reversing immunosuppression and overcoming chemoresistance (103,104).
Addressing the aforementioned challenges will notably advance the application of exosomes in PC research and therapy. The development of more efficient, simpler and cost-effective techniques in isolating and extracting exosomes represents a key and urgent breakthrough warranted in the field. Simultaneously, establishing standardized protocols for exosome extraction is key to improving operational efficiency and minimizing sample loss. Furthermore, systematic comparative studies should be performed to clarify the advantages and suitable scenarios of exosomes over traditional nanocarriers such as liposomes in drug delivery. Lastly, active efforts are warranted to promote the translation of exosome-based therapies for PC from basic research to clinical trials.
In summary, exosomes hold notable potential as a therapeutic strategy for PC. Future research should focus on further understanding of their functional mechanisms, optimizing their isolation and extraction techniques and facilitating their clinical translation, with the potential goal of offering novel treatment options for patients with PC in the clinic at the earliest opportunity.
Conclusions
Exosomes, as key mediators of intercellular communication, are involved in the occurrence and progression of PC. The present review systematically elaborated on the dual roles of exosomes in PC and analyzed their mechanisms of action at the molecular and signaling pathway levels. Previous research has identified that exosomes primarily promote the initiation and progression of PC through the following pathways: i) Directly regulating tumor cell behavior, driving the growth and proliferation of PC cells; ii) remodeling the immunosuppressive microenvironment, providing a more favorable environment for the growth and proliferation of PC cells; iii) inducing therapeutic resistance, thereby reducing the efficacy of drug treatments; and iv) regulating lipid metabolism, by reprogramming metabolism, affects the TME, thereby further supporting the progression of PC.
However, exosomes also exhibit potential in inhibiting the development of PC: i) Specific proteins, nucleic acids and other components carried by exosomes potentially offer novel avenues for the early diagnosis and prognosis assessment of PC; ii) certain exosomes can inhibit the progression of PC through different signaling pathways or by modulating the TME; iii) exosomes can serve as notable carriers for drugs effectively treating PC, enabling targeted delivery of therapeutic agents to achieve enhanced efficacy and reduced toxicity; and iv) the regulatory strategies based on the ‘exosome-lipid metabolism-TME’ axis may become a novel target for the treatment of PC.
The functional duality exhibited by exosomes in PC reflects their complex role in tumor biology: Exosomes can both promote malignant tumor progression and hold potential as diagnostic and therapeutic tools. This paradoxical characteristic suggests that their functions may be regulated by multiple factors, including the source cells, cargo composition and recipient microenvironment. Future research is warranted to further elucidate the specific mechanisms by which exosomes transmit information between different tumor stages and cell types and explore the molecular basis of their transformation from the ‘dark side’ to the ‘bright side’.
In conclusion, a comprehensive understanding of the dual roles of exosomes in PC will not only help further the understanding of the communication network within the TME but also provide a notable basis in developing novel diagnostic strategies and therapeutic methods based on exosomes. Advancement in the clinical translation of exosomes may potentially open novel paths for the early detection and precision treatment of PC in the future.
Acknowledgements
Not applicable.
Availability of data and materials
Not applicable.
Authors' contributions
ZG contributed to the conception and overall design of the study, drafted the manuscript and prepared the figures and tables. QL reviewed and revised the manuscript. All authors read and approved the final manuscript. Data authentication is not applicable.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
ReferencesSiegelRLGiaquintoANJemalACancer statistics, 2024CA Cancer J Clin741249202438230766RawlaPSunkaraTGaduputiVEpidemiology of pancreatic cancer: Global trends, etiology and risk factorsWorld J Oncol101027201910.14740/wjon116630834048ConroyTHammelPHebbarMBen AbdelghaniMWeiACRaoulJLChonéLFrancoisEArtruPBiagiJJFOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancerN Engl J Med37923952406201810.1056/NEJMoa180977530575490StoopTFJavedAAObaAKoerkampBGSeufferleinTWilminkJWBesselinkMGPancreatic cancerLancet40511821202202510.1016/S0140-6736(25)00261-240187844SabaHGogginsMFamilial pancreatic cancerGastroenterol Clin North Am51561575202210.1016/j.gtc.2022.06.00636153110WoodLDYurgelunMBGogginsMGGenetics of familial and sporadic pancreatic cancerGastroenterology15620412055201910.1053/j.gastro.2018.12.03930660730NgamruengphongSCantoMIScreening for pancreatic cancerSurg Clin North Am9612231233201610.1016/j.suc.2016.07.01627865274KleinAPBruneKAPetersenGMGogginsMTersmetteACOfferhausGJGriffinCCameronJLYeoCJKernSHrubanRHProspective risk of pancreatic cancer in familial pancreatic cancer kindredsCancer Res6426342638200410.1158/0008-5472.CAN-03-382315059921TorphyRJZhuYSchulickRDImmunotherapy for pancreatic cancer: Barriers and breakthroughsAnn Gastroenterol Surg2274281201810.1002/ags3.1217630003190RaposoGStoorvogelWExtracellular vesicles: Exosomes, microvesicles, and friendsJ Cell Biol200373383201310.1083/jcb.20121113823420871HamSLimaLGChaiEPZMullerALobbRJKrumeichSWenSWWiegmansAPMöllerABreast cancer-derived exosomes alter macrophage polarization via gp130/STAT3 signalingFront Immunol9871201810.3389/fimmu.2018.0087129867925Costa-SilvaBAielloNMOceanAJSinghSZhangHThakurBKBeckerAHoshinoAMarkMTMolinaHPancreatic cancer exosomes initiate pre-metastatic niche formation in the liverNat Cell Biol17816826201510.1038/ncb316925985394HanSGonzaloDHFeelyMRinaldiCBelsareSZhaiHKalraKGerberMHForsmarkCEHughesSJStroma-derived extracellular vesicles deliver tumor-suppressive miRNAs to pancreatic cancer cellsOncotarget957645777201710.18632/oncotarget.2353229464032ZhangHFreitasDKimHSFabijanicKLiZChenHMarkMTMolinaHMartinABBojmarLIdentification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionationNat Cell Biol20332343201810.1038/s41556-018-0040-429459780Al-NedawiKMeehanBMicallefJLhotakVMayLGuhaARakJIntercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cellsNat Cell Biol10619624200810.1038/ncb172518425114RaimondoSSaievaLCorradoCFontanaSFlugyARizzoADe LeoGAlessandroRChronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanismCell Commun Signal138201510.1186/s12964-015-0086-x25644060YukawaHSuzukiKAokiKArimotoTYasuiTKajiNIshikawaTOchiyaTBabaYImaging of angiogenesis of human umbilical vein endothelial cells by uptake of exosomes secreted from hepatocellular carcinoma cellsSci Rep86765201810.1038/s41598-018-24563-029713019ZhaoHYangLBaddourJAchrejaABernardVMossTMariniJCTudaweTSeviourEGSan LucasFATumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolismElife5e10250201610.7554/eLife.1025026920219QinCLiTLinCZhaoBLiZZhaoYWangWThe systematic role of pancreatic cancer exosomes: distant communication, liquid biopsy and future therapyCancer Cell Int24264202410.1186/s12935-024-03456-539054529OliveiraCCalmeiroJCarrascalMAFalcãoAGomesCMiguel NevesBTeresa CruzMExosomes as new therapeutic vectors for pancreatic cancer treatmentEur J Pharm Biopharm161414202110.1016/j.ejpb.2021.02.00233561524ChargaffEWestRThe biological significance of the thromboplastic protein of bloodJ Biol Chem166189197194610.1016/S0021-9258(17)34997-920273687TramsEGLauterCJSalemNJrHeineUExfoliation of membrane ecto-enzymes in the form of micro-vesiclesBiochim Biophys Acta6456370198110.1016/0005-2736(81)90512-56266476JohnstoneRMAdamMHammondJROrrLTurbideCVesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes)J Biol Chem26294129420198710.1016/S0021-9258(18)48095-73597417JohnstoneRMBianchiniATengKReticulocyte maturation and exosome release: Transferrin receptor containing exosomes shows multiple plasma membrane functionsBlood7418441851198910.1182/blood.V74.5.1844.18442790208YuLLZhuJLiuJXJiangFNiWKQuLSNiRZLuCHXiaoMBA comparison of traditional and novel methods for the separation of exosomes from human samplesBiomed Res Int20183634563201810.1155/2018/363456330148165LatheGHRuthvenCRThe separation of substances on the basis of their molecular weights, using columns of starch and waterBiochem J60xxxiv195513249976ChengHFangHXuRDFuMQChenLSongXYQianJYZouYZMaJYGeJBDevelopment of a rinsing separation method for exosome isolation and comparison to conventional methodsEur Rev Med Pharmacol Sci2350745083201931298362YooCEKimGKimMParkDKangHJLeeMHuhNA direct extraction method for microRNAs from exosomes captured by immunoaffinity beadsAnal Biochem4319698201210.1016/j.ab.2012.09.00822982508WunschBHSmithJTGiffordSMWangCBrinkMBruceRLAustinRHStolovitzkyGAstierYNanoscale lateral displacement arrays for the separation of exosomes and colloids down to 20 nmNat Nanotechnol11936940201610.1038/nnano.2016.13427479757LiPKaslanMLeeSHYaoJGaoZProgress in exosome isolation techniquesTheranostics7789804201710.7150/thno.1813328255367AldertonGKDiagnosis: Fishing for exosomesNat Rev Cancer15453201510.1038/nrc399026205334ColomboMRaposoGThéryCBiogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesiclesAnnu Rev Cell Dev Biol30255289201410.1146/annurev-cellbio-101512-12232625288114SimonsMRaposoGExosomes-vesicular carriers for intercellular communicationCurr Opin Cell Biol21575581200910.1016/j.ceb.2009.03.00719442504StoorvogelWStrousGJGeuzeHJOorschotVSchwartzALLate endosomes derive from early endosomes by maturationCell65417427199110.1016/0092-8674(91)90459-C1850321HansonPICashikarAMultivesicular body morphogenesisAnnu Rev Cell Dev Biol28337362201210.1146/annurev-cellbio-092910-15415222831642SahuRKaushikSClementCCCannizzoESScharfBFollenziAPotolicchioINievesECuervoAMSantambrogioLMicroautophagy of cytosolic proteins by late endosomesDev Cell20131139201110.1016/j.devcel.2011.02.01121238931SkotlandTHessvikNPSandvigKLlorenteAExosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biologyJ Lipid Res60918201910.1194/jlr.R08434330076207ThéryCZitvogelLAmigorenaSExosomes: Composition, biogenesis and functionNat Rev Immunol2569579200210.1038/nri85512154376GusachenkoONZenkovaMAVlassovVVNucleic acids in exosomes: Disease markers and intercellular communication moleculesBiochemistry (Mosc)7817201310.1134/S000629791301001X23379554ValadiHEkströmKBossiosASjöstrandMLeeJJLötvallJOExosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cellsNat Cell Biol9654659200710.1038/ncb159617486113SadikNCruzLGurtnerARodosthenousRSDusoswaSAZieglerOVan SolingeTSWeiZSalvador-GaricanoAMGyorgyBExtracellular RNAs: A new awareness of old perspectivesMethods Mol Biol1740115201810.1007/978-1-4939-7652-2_129388131OliveiraGPJrZigonERogersGDavodianDLuSJovanovic-TalismanTJonesJTiggesJTyagiSGhiranICDetection of extracellular vesicle RNA using molecular beaconsiScience23100782202010.1016/j.isci.2019.10078231958756MitchellPSParkinRKKrohEMFritzBRWymanSKPogosova-AgadjanyanELPetersonANoteboomJO'BriantKCAllenACirculating microRNAs as stable blood-based markers for cancer detectionProc Natl Acad Sci USA1051051310518200810.1073/pnas.080454910518663219XieZYinXGongBNieWWuBZhangXHuangJZhangPZhouZLiZSalivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancerCancer Prev Res (Phila)8165173201510.1158/1940-6207.CAPR-14-019225538087de Gonzalo-CalvoDKennewegFBangCToroRvan der MeerRWRijzewijkLJSmitJWLambHJLlorente-CortesVThumTCirculating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetesSci Rep637354201610.1038/srep3735427874027SunWRenYLuZZhaoXThe potential roles of exosomes in pancreatic cancer initiation and metastasisMol Cancer19135202010.1186/s12943-020-01255-w32878635HonselmannKCFinettiPBirnbaumDJMonsalveCSWellnerUFBeggSKSNakagawaAHankTLiAGoldsworthyMANeoplastic-stromal cell cross-talk regulates matrisome expression in pancreatic cancerMol Cancer Res1818891902202010.1158/1541-7786.MCR-20-043932873625NodaKSatoYOkadaYNishidaKKawanoYTanahashiTBandoMOkamotoKTakeharaMSogabeMExosomal miR-199a-3p secreted from cancer-associated adipocytes promotes pancreatic cancer progressionCancer Med13e70265202410.1002/cam4.7026539431622ZhangLChenYDaiYMouWDengPJinYXuJJinYCancer-associated fibroblast-derived exosome Leptin promotes malignant biological lineage in pancreatic ductal adenocarcinoma by regulating ABL2 via miR-224-3pMol Biol Rep51995202410.1007/s11033-024-09928-139298063ZhouBLeiJHWangQQuTFChaLCZhanHXLiuSLHuXSunCDGuoWDCancer-associated fibroblast-secreted miR-421 promotes pancreatic cancer by regulating the SIRT3/H3K9Ac/HIF-1α axisKaohsiung J Med Sci3810801092202210.1002/kjm2.1259036200682FengSChenRHuangHOngMJiangJCuiJLingQCancer cell-derived exosomal miR-519a/522-5p promotes pancreatic cancer progression by enhancing warburg effectAnn Surg Oncol3270687081202510.1245/s10434-025-17540-140483314WuJPancreatic cancer-derived exosomes promote the proliferation, invasion, and metastasis of pancreatic cancer by the miR-3960/TFAP2A axisJ Oncol20223590326202210.1155/2022/359032636284637LiuPZuFChenHYinXTanXExosomal DNAJB11 promotes the development of pancreatic cancer by modulating the EGFR/MAPK pathwayCell Mol Biol Lett2787202210.1186/s11658-022-00390-036209075ChenYLeiYLiJWangXLiGMacrophage-derived exosomal microRNAs promote metastasis in pancreatic ductal adenocarcinomaInt Immunopharmacol129111590202410.1016/j.intimp.2024.11159038316083YangYGuoZChenWWangXCaoMHanXZhangKTengBCaoJWuWM2 macrophage-derived exosomes promote angiogenesis and growth of pancreatic ductal adenocarcinoma by targeting E2F2Mol Ther2912261238202110.1016/j.ymthe.2020.11.02433221435WangTYeLZhouYZhangXLiRZhouYWengJMoQYuYPancreatic cancer-derived exosomal miR-510 promotes macrophage M2 polarization and facilitates cancer cell aggressive phenotypesHum Cell3817202410.1007/s13577-024-01144-039528705HeZWangJZhuCXuJChenPJiangXChenYJiangJSunCExosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasisCancer Lett548215751202210.1016/j.canlet.2022.21575135718269YangWZhengYZhouHLiangRHuCCancer-associated fibroblast-secreted exosomes regulate macrophage polarization in pancreatic cancer via the NOD1 pathwayJ Biochem Mol Toxicol39e70126202510.1002/jbt.7012639756063ZhongDLiaoYChenWHuangXLiuJWangZTYROBP promotes the spread of pancreatic cancer by causing M2 TAM polarizationJ Gastroenterol Hepatol3929262939202410.1111/jgh.1678339496400WangCXuSQinYTumor-derived exosome PPP3CB induce gemcitabine resistance by regulating miR-298/STAT3 in pancreatic cancerHeliyon10e36434202410.1016/j.heliyon.2024.e3643439253142BhattacharyaSPalKSharmaAKDuttaSKLauJSYanIKWangEElkhananyAAlkharfyKMSanyalAGAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathwaysPLoS One9e114409201410.1371/journal.pone.011440925469510YangZZhaoNCuiJWuHXiongJPengTExosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210Cell Oncol (Dordr)43123136202010.1007/s13402-019-00476-631713003QiRBaiYLiKLiuNXuYDalEWangYLinRWangHLiuZCancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAsDrug Resist Updat68100960202310.1016/j.drup.2023.10096037003125MikamoriMYamadaDEguchiHHasegawaSKishimotoTTomimaruYAsaokaTNodaTWadaHKawamotoKMicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinomaSci Rep742339201710.1038/srep4233928198398XuSPengXWangZLeCWuXZengZZengSZhangCQiuMZouXFABP7-mediated lipid-laden macrophages drive the formation of pre-metastatic niche and liver metastasisInt J Biol Sci2143884409202510.7150/ijbs.11075040765822YangYGuHZhangKGuoZWangXWeiQWengLHanXLvYCaoMExosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancerBMC Cancer23789202310.1186/s12885-023-11239-w37612627MashouriLYousefiHArefARAhadiAMMolaeiFAlahariSKExosomes: Composition, biogenesis, and mechanisms in cancer metastasis and drug resistanceMol Cancer1875201910.1186/s12943-019-0991-530940145AdamskaAElaskalaniOEmmanouilidiAKimMAbdol RazakNBMetharomPFalascaMMolecular and cellular mechanisms of chemoresistance in pancreatic cancerAdv Biol Regul687787201810.1016/j.jbior.2017.11.00729221990FanJWeiQKoayEJLiuYNingBBernardPWZhangNHanHKatzMHZhaoZHuYChemoresistance transmission via exosome-mediated EphA2 transfer in pancreatic cancerTheranostics859865994201810.7150/thno.2665030613276GuoWYingPMaRJingZMaGLongJLiGLiuZLiquid biopsy analysis of lipometabolic exosomes in pancreatic cancerCytokine Growth Factor Rev736977202310.1016/j.cytogfr.2023.07.00637684117SøreideKIsmailWRoalsøMGhotbiJZahariaCEarly diagnosis of pancreatic cancer: Clinical premonitions, timely precursor detection and increased curative-intent surgeryCancer Control3010732748231154711202310.1177/1073274823115471136916724FangXLanHJinKQianJPancreatic cancer and exosomes: role in progression, diagnosis, monitoring, and treatmentFront Oncol131149551202310.3389/fonc.2023.114955137287924OdakaHHiemoriKShimodaAAkiyoshiKTatenoHCD63-positive extracellular vesicles are potential diagnostic biomarkers of pancreatic ductal adenocarcinomaBMC Gastroenterol22153202210.1186/s12876-022-02228-735350978ChenJYaoDChenWLiZGuoYZhuFHuXSerum exosomal miR-451a acts as a candidate marker for pancreatic cancerInt J Biol Markers377480202210.1177/1724600821107001835001683YoshiokaYShimomuraMSaitoKIshiiHDokiYEguchiHNakatsuraTItoiTKurodaMMoriMOchiyaTCirculating cancer-associated extracellular vesicles as early detection and recurrence biomarkers for pancreatic cancerCancer Sci11334983509202210.1111/cas.1550035848896HongLXuLJinLXuKTangWZhuYQiuXWangJExosomal circular RNA hsa_circ_0006220, and hsa_circ_0001666 as biomarkers in the diagnosis of pancreatic cancerJ Clin Lab Anal36e24447202210.1002/jcla.2444735446993TaniguchiTIdenoNArakiTMiuraSYamamotoMNakafusaTHigashijimaNYamamotoTTamuraKNakamuraSMicroRNA-20a in extracellular vesicles derived from duodenal fluid is a possible biomarker for pancreatic ductal adenocarcinomaDEN Open4e333202410.1002/deo2.33338434144Di PaceALPelosiAFiorePFTuminoNBesiFQuatriniLSantopoloSVaccaPMorettaLMicroRNA analysis of Natural Killer cell-derived exosomes: the microRNA let-7b-5p is enriched in exosomes and participates in their anti-tumor effects against pancreatic cancer cellsOncoimmunology122221081202310.1080/2162402X.2023.222108137304055HasogluIKaratug KacarAThe therapeutic effects of exosomes the first time isolated from pancreatic islet-derived progenitor cells in the treatment of pancreatic cancerProtoplasma261281291202410.1007/s00709-023-01896-w37798610ZhengYZouXLiQJiangDZhuFWuYExosomes derived from umbilical cord blood NK cells inhibit the progression of pancreatic cancer by targeting ROS-mediated mitochondrial dysfunctionSaudi Pharm J338202510.1007/s44446-025-00009-340397293XuYLiuNWeiYZhouDLinRWangXShiBAnticancer effects of miR-124 delivered by BM-MSC derived exosomes on cell proliferation, epithelial mesenchymal transition, and chemotherapy sensitivity of pancreatic cancer cellsAging (Albany NY)121966019676202010.18632/aging.10399733040049TangZGChenTMLuYWangZWangXCKongYHuman bone marrow mesenchymal stem cell-derived exosomes loaded with gemcitabine inhibit pancreatic cancer cell proliferation by enhancing apoptosisWorld J Gastrointest Oncol1640064013202410.4251/wjgo.v16.i9.400639350998ZhaoYZhengYZhuYZhangYZhuHLiuTM1 macrophage-derived exosomes loaded with gemcitabine and deferasirox against chemoresistant pancreatic cancerPharmaceutics131493202110.3390/pharmaceutics1309149334575569LiYJWuJYWangJMHuXBCaiJXXiangDXGemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancerActa Biomater101519530202010.1016/j.actbio.2019.10.02231629893ZhanTZouYHanZTianXChenMLiuJYangXZhuQLiuMChenWSingle-cell sequencing combined with spatial transcriptomics reveals that the IRF7 gene in M1 macrophages inhibits the occurrence of pancreatic cancer by regulating lipid metabolism-related mechanismsClin Transl Med14e1799202410.1002/ctm2.179939118300LiSDongRKangZLiHWuXLiTExosomes: Another intercellular lipometabolic communication mediators in digestive system neoplasms?Cytokine Growth Factor Rev7393100202310.1016/j.cytogfr.2023.06.00537541791LiJLiYChenSDuanWKongXWangYZhouLLiPZhangCDuLWangCHighly sensitive exosome detection for early diagnosis of pancreatic cancer using immunoassay based on hierarchical surface-enhanced raman scattering substrateSmall Methods6e2200154202210.1002/smtd.20220015435460217YuZYangYFangWHuPLiuYShiJDual tumor exosome biomarker co-recognitions based nanoliquid biopsy for the accurate early diagnosis of pancreatic cancerACS Nano171138411395202310.1021/acsnano.3c0067437288703YinTXuLGilBMeraliNSokolikovaMSGaboriauDCALiuDSKMuhammad MustafaANAlodanSChenMGraphene sensor arrays for rapid and accurate detection of pancreatic cancer exosomes in patients' blood plasma samplesACS Nano171461914631202310.1021/acsnano.3c0181237470391JabbariNKarimipourMKhaksarMAkbariazarEHeidarzadehMMojaradBAftabHRahbarghaziRRezaieJTumor-derived extracellular vesicles: Insights into bystander effects of exosomes after irradiationLasers Med Sci35531545202010.1007/s10103-019-02880-831529349JabbariNAkbariazarEFeqhhiMRahbarghaziRRezaieJBreast cancer-derived exosomes: Tumor progression and therapeutic agentsJ Cell Physiol23563456356202010.1002/jcp.2966832216070SunMZhangHMaYWangSChenJCuiYZhangYHuSZhouDZhangPIn situ programming of the tumor microenvironment to alleviate immunosuppression for pancreatic cancer immunotherapyAdv Sci (Weinh)12e04008202510.1002/advs.20250400840548883van NielGCarterDRFClaytonALambertDWRaposoGVaderPChallenges and directions in studying cell-cell communication by extracellular vesiclesNat Rev Mol Cell Biol23369382202210.1038/s41580-022-00460-335260831RoyoFThéryCFalcón-PérezJMNieuwlandRWitwerKWMethods for separation and characterization of extracellular vesicles: Results of a worldwide survey performed by the ISEV rigor and standardization subcommitteeCells91955202010.3390/cells909195532854228RamirezMIAmorimMGGadelhaCMilicIWelshJAFreitasVMNawazMAkbarNCouchYMakinLTechnical challenges of working with extracellular vesiclesNanoscale10881906201810.1039/C7NR08360B29265147GhanamJChettyVKZhuXLiuXGellériMBarthelLReinhardtDCremerCThakurBKSingle molecule localization microscopy for studying small extracellular vesiclesSmall19e2205030202310.1002/smll.20220503036635058ZhangYPLobanovaEDworkinAFurlepaMYangWSBurkeMMengJXPotterNSalaRLKahanawitaLImproved imaging surface for quantitative single-molecule microscopyACS Appl Mater Interfaces163725537264202410.1021/acsami.4c0651238979642JuYHuYYangPXieXFangBExtracellular vesicle-loaded hydrogels for tissue repair and regenerationMater Today Bio18100522202210.1016/j.mtbio.2022.10052236593913LuYZhouHHanCGongYLiYXiaYLiangBYangHWangZEnhanced therapeutic impact of Shikonin-encapsulated exosomes in the inhibition of colorectal cancer progressionNanotechnology35202410.1088/1361-6528/ad61f2ZhaoBLinHJiangXLiWGaoYLiMYuYChenNGaoJExosome-like nanoparticles derived from fruits, vegetables, and herbs: Innovative strategies of therapeutic and drug deliveryTheranostics1445984621202410.7150/thno.9709639239509LiangYDuanLLuJXiaJEngineering exosomes for targeted drug deliveryTheranostics1131833195202110.7150/thno.5257033537081HerrmannIKWoodMJAFuhrmannGExtracellular vesicles as a next-generation drug delivery platformNat Nanotechnol16748759202110.1038/s41565-021-00931-234211166PhutelaKBalASinghNSharmaSHydroxycitrate-loaded exosomes demonstrate enhanced therapeutic efficacy against lung adenocarcinoma by inhibiting the metabolic enzyme ATP citrate lyaseNanoscale Adv738463858202510.1039/D5NA00094G40401277MohammedOAhmed AssayeMAlemayehuETufaAGenetSExosomes in cancer metabolism and drug resistance: A reviewBiomol Biomed26730745202510.17305/bb.2025.1329541190394
Classification of extracellular vesicles. Green arrows indicate microvesicles (100–1,000 nm), which bud directly from the cell membrane; red arrows indicate exosomes (30–150 nm), which are released upon fusion of multivesicular bodies with the plasma membrane; and purple arrows indicate apoptotic bodies (500–5,000 nm), which are released during apoptosis.
Classification of extracellular vesicles. Green arrows indicate microvesicles (100–1,000 nm), which bud directly from the cell membrane; red arrows indicate exosomes (30–150 nm), which are released upon fusion...
Biogenesis and composition of exosomes. Black arrows indicate the molecular mechanisms and trafficking pathways involved in exosome biogenesis and release. Exosomes originate from early endosomes, which progressively mature into late endosomes. Late endosomes undergo inward budding to form ILVs through ESCRT-dependent mechanisms, tetraspanins and ceramide-induced pathways, resulting in the generation of MVBs. MVBs have two distinct fates: Fusion with lysosomes for degradation or fusion with the plasma membrane via RAB GTPases and SNARE proteins to release exosomes. The released exosomes carry diverse molecular cargo, including MHC class I/II molecules, integrins, proteins, lipids, RNA and tetraspanins (CD9, CD63, CD81). ESCRT, endosomal sorting complex required for transport; MVBs, multivesicular bodies; ILV, intraluminal vesicles; MHC, major histocompatibility complex; RAB GTPase, Ras-related in brain; SNARE, soluble N-ethylmaleimide-sensitive factor activating protein receptor.
Biogenesis and composition of exosomes. Black arrows indicate the molecular mechanisms and trafficking pathways involved in exosome biogenesis and release. Exosomes originate from early endosomes, which progressively mature...
Mechanisms of exosomes in promoting the initiation and progression of PC. Black arrows indicate the cellular sources of exosomes and their mediated biological functions. Exosomes derived from CAFs, adipocytes, macrophages, PC cells and PC stem cells carry diverse cargos, including miRNAs (miR-199a-3p, miR-224-3p, miR-421, miR-519a, miR-522-5p, miR-3960, miR-202-5p, miR-142-5p, miR-510, miR-155, miR-210, miR-3173-5p), lncRNA FGD5-AS1 and proteins (DNAJB11, E2F2, TYROBP, PTGS2, PPP3CB, ABCG2, ACADM, fatty acid binding protein 7). These exosomal cargos contribute to PC progression through multiple mechanisms: (A) Driving tumor growth and cell proliferation, (B) shaping the immunosuppressive microenvironment, (C) inducing therapeutic resistance, and (D) regulating lipid metabolism and the TME. CAFs, cancer-associated fibroblasts; PC, pancreatic cancer; DNAJB11, DNA J homolog subfamily B member 11; E2F2, E2F transcription factor 2; miR, microRNA; lncRNA, long non-coding RNA; lncRNA FGD5-AS1, FGD5 antisense RNA 1; PTGS2, prostaglandin-endoperoxide synthase 2; TYROBP, tyrosine kinase-binding protein; PPP3CB, protein phosphatase 3 catalytic subunit β isoform; ABCG2, ATP-binding cassette transporter G2; ACADM, medium-chain acyl-CoA dehydrogenase; TME, tumor microenvironment.
Mechanisms of exosomes in promoting the initiation and progression of PC. Black arrows indicate the cellular sources of exosomes and their mediated biological functions. Exosomes derived from CAFs, adipocytes, macrophages...
Mechanisms of exosomes in the diagnosis and treatment of PC. Black arrows indicate the multifaceted applications of exosomes in PC research. (A) Exosomes derived from serum, platelets, plasma and duodenal fluid carry various molecules, including CD41+, CD63+, CD61+, GPRC5C, EPS8, miR-451a, miR-20a, hsa_circ_0001666 and hsa_circ_0006220, serving as biomarkers for liquid biopsy. Additionally, researchers have developed advanced exosome detection systems, such as nanoscale SERS substrates, graphene transistor sensors and bispecific antibody-based platforms, to improve the accuracy of early diagnosis. (B) Exosomes derived from UC-NK cells, BMSCs and islet-derived progenitor cells can directly kill PC cells through distinct mechanisms of action. (C) As drug delivery carriers, exosomes derived from BMSCs, PC cells and macrophages can be utilized for therapeutic agent delivery. (D) Regarding ‘Exosomes-lipid metabolism-TME’ therapeutic strategies, exosomes derived from macrophages and PC cells are involved in therapeutic interventions targeting this regulatory axis. PC, pancreatic cancer; SERS, surface-enhanced Raman spectroscopy; GPRC5C, G protein-coupled receptor class C group 5 member C; EPS8, epidermal growth factor receptor pathway substrate 8; UC-NK cells, umbilical cord blood natural killer cells; BMSCs, bone marrow mesenchymal stem cells; TME, tumor microenvironment; miR, microRNA; hsa_circ, Homo sapiens circular RNA.
Mechanisms of exosomes in the diagnosis and treatment of PC. Black arrows indicate the multifaceted applications of exosomes in PC research. (A) Exosomes derived from serum, platelets, plasma and duodenal fluid carry various...
Role of exosomes in the pathogenesis and progression of PC.
A, Exosomes drive tumor growth and tumor cell proliferation
Cellular origins of exosomes
Specific mechanisms of action
(Refs.)
CAAs
miR-199a-3p mediates the SOCS7/STAT3/SAA1 pathway
(48)
CAFs
miR-224-3p regulates ABL2; miR-421 functions through the SIRT3/H3K9Ac/HIF-1α axis
(49,50)
PC cells
miR-519a/522-5p enhances the Warburg effect; miR-3960 mediates the TFAP2A axis; DNAJB11 protein regulates the EGFR/MAPK pathway
(51–53)
Macrophages
miR-202-5p and miR-142-5p enhance the invasive ability of PC cells
(54)
M2 type macrophages
Targeting E2F2 promotes tumor angiogenesis
(55)
B, Exosomes shape the immunosuppressive microenvironment
Cellular origins of exosomes
Specific mechanisms of action
(Refs.)
PC cells
miR-510 and lncRNA FGD5-AS1 promote M2 macrophages polarization
(56,57)
CAFs
Carrying PTGS2 activates the NOD1 and induces M2 macrophages polarization
(58)
Tumor-associated macrophages
TYROBP mediates the CD44/AKT/ERK pathway
(59)
C, Exosomes for induction therapy resistance
Cellular origins of exosomes
Specific mechanisms of action
(Refs.)
PC cells
PPP3CB inhibits miR-298 and upregulates STAT3 expression; ABCG2 is induced to function as a drug efflux pump in vitro; miR-155 targets TP53INP1 to confer antiapoptotic activity
(60,61,64)
PC stem cells
miR-210 triggers the mTOR signaling pathway
(62)
CAFs
miR-3173-5p mediates the ACSL4 pathway to inhibit ferroptosis
(63)
D, Exosomes for the regulation of lipid metabolism and the TME
Cellular origins of exosomes
Specific mechanisms of action
(Refs.)
Macrophages
Through metabolic reprogramming, CD8+ T-cell function is impaired and tumor cell proliferation is promoted
(65)
PC cells
ACADM regulates fatty acid metabolism and ferroptosis
(66)
CAAs, cancer-associated adipocytes; CAFs, cancer-associated fibroblasts; SOCS7/STAT3/SAA1, suppressor of cytokine signaling 7/signal transducer and activator of transcription 3/serum amyloid A1; miR, microRNA; SIRT3/H3K9Ac/HIF-1α, silent information regulator 3/histone 3 lysine 9 acetylation/hypoxia inducible factor 1α; PC, pancreatic cancer; TFAP2A, transcription factor activator protein-2α; E2F2, E2F transcription factor 2; PTGS2, prostaglandin-endoperoxide synthase 2; TYROBP, tyrosine kinase-binding protein; ABCG2, ATP-binding cassette transporter G2; ACSL4, acyl-CoA synthetase long-chain family member 4; TME, tumor microenvironment; ACADM, medium-chain acyl-CoA dehydrogenase; TP53INP1, tumor protein 53 inducible nuclear protein 1; DNAJB11, DnaJ heat shock protein family (HSP40) member B11 protein; lncRNA, long non-coding RNA; NOD1, nucleotide-binding oligomerization domain-containing protein 1; PPP3CB, protein phosphatase 3 catalytic subunit β.
Role of exosomes in the diagnosis and treatment of PC.
A, Exosomes as a biomarker for liquid biopsy
Cellular origins of exosomes
Specific molecules and mechanisms of action
(Refs.)
Serum
CD63+ cells; miR-451a; GPRC5C; EPS8
(73–75)
Platelet
CD41+ and CD61+ cells
(73)
Plasma
hsa_circ_0001666 and hsa_circ_0006220
(76)
Duodenal fluid
miR-20a
(77)
B, Exosomes as a direct tool in treating PC
Cellular origins of exosomes
Specific molecules and mechanisms of action
(Refs.)
NK cells
Upregulates the expression level of let-7b-5p in PC cells and inhibits tumor cell proliferation by targeting the cell cycle regulator CDK6
(78)
Islet derived progenitor cells
Selectively kills PC cells without causing harm to normal cells
(79)
UC-NK cells
Enters PANC-1 cells via endocytosis, induces mitochondrial oxidative damage and suppresses PANC-1 cell progression
(80)
BMSCs
miR-124 exhibits anti-PC activity
(81)
C, Exosomes as a carrier for drug delivery
Cellular origins of exosomes
Specific molecules and mechanisms of action
(Refs.)
BMSCs
Loaded with gemcitabine, it enhances apoptosis and inhibits the proliferation of PC cells
(82)
M1 type macrophages
Loaded with gemcitabine and deferasirox, it overcomes inherent drug resistance
(83)
PC cells
Loaded with gemcitabine, it markedly promotes drug uptake in cancer cells
Inhibits the lipid metabolism pathway, thereby reducing the proliferation, migratory and invasive abilities of PC cells and simultaneously promoting their apoptosis
(85)
PC cells
Involved in lipid metabolism and regulating the TME
(86)
GPRC5C, G protein-coupled receptor class C group 5 member C; EPS8, epidermal growth factor receptor pathway substrate 8; PC, pancreatic cancer; UC-NK, umbilical cord blood natural killer; BMSCs, bone marrow mesenchymal stem cells; TME, tumor microenvironment; miR, microRNA; hsa_circ, Homo sapiens circular RNA.